| Name | Title | Contact Details |
|---|---|---|
Michael Webb |
Director Of Information Technology | Profile |
Creating precisely tuned medicines so patients can breathe freely, we are pioneering a new therapeutic approach to treat debilitating ear, nose and throat diseases that impact the lives of millions of people. Lyra Therapeutics is a clinical-stage company pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients. Lyra`s transmucosal therapeutic system, now being evaluated in a clinical study, directly targets tissues that are difficult or impossible to access with existing therapies. Building on expertise in materials science, drug development and formulation, the Lyra team has developed a proprietary platform that enables sustained, local delivery of medications over an extended period of time. Based on clinical results, this new therapeutic approach has the potential to provide significantly improved patient outcomes beyond the limited treatment and surgical options currently available for ENT diseases. Headquartered in the Boston area, Lyra Therapeutics was founded by George Whitesides and Robert Langer, academic luminaries in the fields of chemistry, materials science and biotechnology, and is backed by leading life science investors.
Evotec is a Winchester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kyowa Hakko Kirin Pharma is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products for the treatment of lung diseases and conditions.